Literature DB >> 9781946

The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.

S E Pinder1, S Murray, I O Ellis, H Trihia, C W Elston, R D Gelber, A Goldhirsch, J Lindtner, H Cortés-Funes, E Simoncini, M J Byrne, R Golouh, C M Rudenstam, M Castiglione-Gertsch, B A Gusterson.   

Abstract

BACKGROUND: Histologic grade is well recognized for its prognostic significance in cases of primary operable invasive breast carcinoma; however, the majority of studies in which grade has been assessed have been based on single-center trials. In addition, the role of grade in predicting response to chemotherapy has not been examined in many previous studies.
METHODS: The authors assessed the value of Nottingham histologic grade (NHG) in a group of 465 patients enrolled in a multicenter, randomized International Breast Cancer Study Group clinical trial of adjuvant chemotherapy for patients with lymph node (LN) positive and LN negative primary breast carcinoma (formerly named Ludwig Trial V).
RESULTS: NHG was a predictor of overall survival for both LN negative and LN positive patients (P=0.045 and P < 0.001, respectively). NHG was associated with a poorer prognosis for both LN positive and LN negative patients, with hazard ratios of 1.651 (P < 0.001) and 1.437 (P=0.045), respectively, for an increase of one grade. Among LN negative patients, this survival disadvantage was observed only for those who received perioperative chemotherapy. For LN positive patients, an increase of one grade resulted in a significant overall survival disadvantage regardless of whether prolonged or perioperative chemotherapy was given. For LN negative patients grouped by grade, there was no observed difference in overall or disease free survival according to whether perioperative chemotherapy or no adjuvant therapy was given. However, LN positive patients with Grade 3 tumors had a significantly greater overall and disease free survival benefit from prolonged chemotherapy than from perioperative chemotherapy (P=0.016 and P=0.013, respectively); LN positive patients with Grade 1 or 2 disease in both treatment arms had comparable overall and disease free survival. A strong correlation between the previously utilized Bloom-Richardson grading system (BRG) and NHG was observed (P < 0.001 and kappa=82%) and no apparent differences in overall and disease free survival were observed between the two systems. NHG did, however, identify a greater proportion of tumors as Grade 1, and BRG identified a greater proportion of breast carcinomas as Grade 3.
CONCLUSIONS: This multicenter clinical study confirms the value of histologic grade, and the authors propose that this technique be used to identify Grade 3, LN positive patients who will benefit from prolonged rather than perioperative chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9781946

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens.

Authors:  E A Rakha; I O Ellis
Journal:  J Clin Pathol       Date:  2007-07-14       Impact factor: 3.411

2.  Breast cancer guidelines for Uganda (2nd Edition 2008).

Authors:  A Gakwaya; M Galukande; A Luwaga; J Jombwe; J Fualal; E Kiguli-Malwadde; P Baguma; A Kanyike; J B Kigula-Mugamba
Journal:  Afr Health Sci       Date:  2008-06       Impact factor: 0.927

3.  Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma.

Authors:  S Frkovic-Grazio; M Bracko
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

4.  Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis.

Authors:  P J Westenend; C J C Meurs; R A M Damhuis
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

Review 5.  [Radiological diagnosis of mammary carcinomas. I: pathology and x-ray mammography].

Authors:  R Schulz-Wendtland; H-P Sinn
Journal:  Radiologe       Date:  2004-05       Impact factor: 0.635

6.  [Morphological response to therapy of breast carcinoma].

Authors:  F Länger; H-J Lück; H H Kreipe
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

7.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study.

Authors:  Christos Sotiriou; Soek-Ying Neo; Lisa M McShane; Edward L Korn; Philip M Long; Amir Jazaeri; Philippe Martiat; Steve B Fox; Adrian L Harris; Edison T Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205

8.  Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count.

Authors:  Ossama Tawfik; Bruce F Kimler; Marilyn Davis; Christopher Stasik; Sue-Min Lai; Matthew S Mayo; Fang Fan; John K Donahue; Ivan Damjanov; Patricia Thomas; Carol Connor; William R Jewell; Holly Smith; Carol J Fabian
Journal:  Virchows Arch       Date:  2007-04-26       Impact factor: 4.064

9.  Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.

Authors:  H P Kourea; A K Koutras; C D Scopa; M N Marangos; E Tzoracoeleftherakis; D Koukouras; H P Kalofonos
Journal:  Mol Pathol       Date:  2003-12

Review 10.  Taxane benefit in breast cancer--a role for grade and chromosomal stability.

Authors:  Roger P A'Hern; Mariam Jamal-Hanjani; A Marcell Szász; Stephen R D Johnston; Jorge S Reis-Filho; Rebecca Roylance; Charles Swanton
Journal:  Nat Rev Clin Oncol       Date:  2013-05-07       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.